Sage Therapeutics Announces Topline Results from the Phase 2 …
WEB16 hours ago · CAMBRIDGE, Mass., October 08, 2024 -- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind,...
Sage Therapeutics to discontinue development of Alzheimer’s drug
WEB16 hours ago · Sage Therapeutics said on Tuesday it will discontinue the development of its Alzheimer's disease drug as it did not meet the main goal in a mid-stage trial.
Sage Therapeutics Announces Topline Results from the Phase 2 …
WEB1 day ago · Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of dalzanemdor (SAGE-718) in participants with mild cognitive impairment (MCI) or mild dementia due to Alzheimer’s Disease (AD).
Sage Therapeutics Announces Discontinuation of the …
WEBSage Therapeutics Announces Discontinuation of the Collaboration with Biogen on the SAGE-324 Program. Sage and Biogen will continue to partner on ZURZUVAE®, the first and only FDA-approved oral treatment for women with postpartum depression.
Sage Therapeutics Announces First Quarter 2024 Financial …
WEBCAMBRIDGE, Mass., April 25, 2024 -- (BUSINESS WIRE)--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported...
FDA Approves ZURZUVAE™ (zuranolone), the First and Only Oral …
WEBAug 4, 2023 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Aug. 4, 2023-- Sage Therapeutics, Inc. (Nasdaq: SAGE) and Biogen Inc. (Nasdaq: BIIB) announced the U.S. Food and Drug Administration (FDA) approved ZURZUVAE TM (zuranolone) 50 mg for adults with postpartum depression (PPD).
Sage Therapeutics to Provide Business Updates at 42nd Annual …
WEBCAMBRIDGE, Mass., January 08, 2024 -- ( BUSINESS WIRE )--Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today...
Sage Therapeutics Announces U.S. Food and Drug Administration …
WEBOct 18, 2023 · Sage is advancing a clinical program for SAGE-718 with multiple ongoing placebo-controlled Phase 2 studies across multiple disease areas, including its potential lead indication, cognitive ...
Sage Therapeutics Announces Continued Positive Zuranolone …
WEBMar 17, 2021 · Zuranolone (SAGE-217) is a once-daily, two-week therapy in development for the treatment of major depressive disorder (MDD) and postpartum depression (PPD). Zuranolone is an investigational oral neuroactive steroid (NAS) GABA A receptor positive allosteric modulator (PAM).
Sage Therapeutics (SAGE) Announces Topline Results from the …
WEB16 hours ago · Sage Therapeutics, Inc. (Nasdaq: SAGE) announced today topline results from LIGHTWAVE, a 12-week, Phase 2 randomized, double-blind, placebo-controlled study to evaluate the effects of...